选择性和脑透性CK1δ抑制剂的基于结构的优化,用于治疗循环节障碍
Stefan McCarver1, Luke Hanna1, Andrew Samant1
1Janssen Research and Development, San Diego, California 92121-1126, United States.
研究人员开发了针对昼夜节律障碍的选择性氨酸激酶1三角酶 (CK1δ) 抑制剂. 这些化合物显示出有前途的大脑透和目标参与,为神经精神疾病提供潜在的治疗途径.
科学领域:
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
- 分子生物学分子生物学
背景情况:
- 神经精神疾病,包括抑郁症和精神分裂症,与昼夜节律障碍有关.
- 氨酸激酶1三角酶 (CK1δ) 在调节24小时睡眠-清醒周期的分子机制方面发挥着至关重要的作用.
研究的目的:
- 确定和开发CK1δ的选择性抑制剂.
- 探索神经精神疾病中昼夜节律失调的新型治疗策略.
主要方法:
- 利用虚拟选来识别初始的双循环pyrazole化合物.
- 采用基于结构的药物设计来优化CK1δ的选择性.
- 使用ex vivo autoradiography评估药物动力学特性,大脑暴露和目标参与.
主要成果:
- 确定了一种独特的"杆翻转"结合模式,用于高CK1δ选择性.
- 开发了具有良好的药理动力学特征的先进类型.
- 在临床前模型中证明了有效的脑部暴露和目标参与.
结论:
- 开发的CK1δ抑制剂具有很高的选择性和大脑透性.
- 这些发现支持CK1δ抑制剂作为与昼夜干扰相关的神经精神疾病的治疗方法的潜力.
更多相关视频
10:33Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors
Published on: October 26, 2015
10:38Monitoring Cell-autonomous Circadian Clock Rhythms of Gene Expression Using Luciferase Bioluminescence Reporters
Published on: September 27, 2012
相关概念视频
Chronopharmacokinetics: Circadian Rhythms and Influence on Drug Response
The time of drug administration is an important factor to consider, as it can influence the toxic dose of a drug. For example, a study conducted by Prins et al. in 1997 examined the effects of the timing of...
Management of Insomnia
Inhibition of Cdk Activity
Circadian Rhythms and Gene Regulation
Sedatives and Hypnotics Drugs: Miscellaneous Agents
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
